12:00 AM
 | 
Jul 05, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avandia rosiglitazone: Additional Phase III data

A post hoc analysis of the open-label, international Phase III BARI 2D trial in 2,368 patients with Type II diabetes and stable coronary artery disease (CAD) showed that Avandia produced a significantly lower rate, as measured by events per 100 patients years of death, MI and stroke vs. no TZD therapy (3.79 vs. 5.81, RR=0.76, p=0.002). Avandia also led to a significantly lower rate of stroke (0.28 vs. 0.77, RR=0.36, p=0.008), but non-significantly...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >